title: Design of a mimic of nonamyloidogenic and bioactive human islet amyloid polypeptide (IAPP) as nanomolar affinity inhibitor of IAPP cytotoxic fibrillogenesis.
abstract: Protein aggregation into cytotoxic oligomers and fibrils in vivo is linked to cell degeneration and the pathogenesis of >25 uncurable diseases, whereas the high aggregation propensity and insolubility of several bioactive polypeptides and proteins in vitro prevent their therapeutic use. Aggregation of human islet amyloid polypeptide (IAPP) into pancreatic amyloid is strongly associated with the pathogenesis of type II diabetes. IAPP is a 37-residue polypeptide that acts as a neuroendocrine regulator of glucose homeostasis. However, IAPP misfolds and self-associates into cytotoxic aggregates and fibrils even at nanomolar concentrations. Because IAPP aggregation causes beta-cell death and prohibits therapeutic application of IAPP in diabetes, we pursued a minimalistic chemical design approach to generate a molecular mimic of a nonamyloidogenic and bioactive IAPP conformation that would still be able to associate with IAPP and thus inhibit its fibrillogenesis and cytotoxicity. We show that the double N-methylated full length IAPP analog [(N-Me)G24, (N-Me)I26]-IAPP (IAPP-GI) is a highly soluble, nonamyloidogenic, and noncytotoxic IAPP molecular mimic and an IAPP receptor agonist. Moreover, IAPP-GI binds IAPP with low nanomolar affinity and completely blocks IAPP cytotoxic self-assembly and fibrillogenesis with activity in the low nanomolar concentration range. Importantly, IAPP-GI dissociates cytotoxic IAPP oligomers and fibrils and is able to reverse their cytotoxicity. Bifunctional soluble IAPP mimics that combine bioactivity with the ability to block and reverse IAPP cytotoxic self-assembly are promising candidates for the treatment of diabetes. Moreover, our amyloid disease inhibitor design concept may be applicable to other protein aggregation diseases.
authors.affiliation: Laboratory of Bioorganic and Medicinal Chemistry, Institute of Biochemistry, University Hospital of the Rheinisch-Westfälische Technische Hochschule Aachen, Pauwelstrasse 30, D-52074 Aachen, Germany.
authors.forename: Li-Mei
authors.initials: LM
authors.lastname: Yan
authors.forename: Marianna
authors.initials: M
authors.lastname: Tatarek-Nossol
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Velkova
authors.forename: Athanasios
authors.initials: A
authors.lastname: Kazantzis
authors.forename: Aphrodite
authors.initials: A
authors.lastname: Kapurniotu
mesh_terms: D000595:Amino Acid Sequence; D000682:Amyloid / Q000037:antagonists & inhibitors* / Q000737:chemistry* / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000686:Amyloidosis / Q000188:drug therapy; D015195:Drug Design; D006801:Humans; D058228:Islet Amyloid Polypeptide; D008024:Ligands; D018716:Molecular Mimicry; D008969:Molecular Sequence Data; D017510:Protein Folding; D017433:Protein Structure, Secondary; D058287:Receptors, Islet Amyloid Polypeptide; D018000:Receptors, Peptide / Q000819:agonists*; D012995:Solubility
chemical_list: C509234:(N-Me)G24, (N-Me)I26-IAPP; D000682:Amyloid; D058228:Islet Amyloid Polypeptide; D008024:Ligands; D058287:Receptors, Islet Amyloid Polypeptide; D018000:Receptors, Peptide